As discussed in Section 5, EZH2 is considered as a promising target for the treatment of HNSCC although further investigations are required to evaluate whether HPV+ and HPV− HNSCC patients could respond differently to EZH2 inhibitors treatments [82]. The gene discussed is EZH2; the disease is head and neck squamous cell carcinoma.